
Shares of Sarepta Therapeutics (NASDAQ:SRPT) plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the company’s experimental treatments.
What Happened: Sarepta Therapeutics confirmed the death of a 51-year-old man who was part of a Phase 1 trial for a gene therapy aimed at treating limb-girdle muscular dystrophy, according to BioCentury. The patient died of liver failure last month after being administered the experimental treatment.